Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex

被引:94
作者
Perfect, JR [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Med & Microbiol, Durham, NC 27710 USA
关键词
D O I
10.1086/429331
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An assessment was made of the efficacy and renal safety of amphotericin B lipid complex ( ABLC) in the treatment of patients with invasive fungal infections caused by moulds other than Aspergillus species, on the basis of a retrospective analysis of data from the Collaborative Exchange of Antifungal Research ( CLEAR) database. Data from CLEAR for 64 patients with zygomycosis were published previously. The database was further queried and yielded results for 28 patients with fusariosis and 84 patients infected with other non- Aspergillus moulds. Of 26 patients with fusariosis whose results could be evaluated, 46% (n = 12) were cured or improved, and an additional 12% (n = 3) were stable. Of 79 patients infected with other non- Aspergillus moulds whose results could be evaluated, 61% (n = 48) were cured or improved, and an additional 15% (n = 12) were stable. In an area with little guidance for therapy, the CLEAR data indicate that ABLC can be an effective broad- spectrum treatment choice for several invasive and refractory non- Aspergillus mould infections.
引用
收藏
页码:S401 / S408
页数:8
相关论文
共 39 条
  • [1] ANAISSIE E, 1989, REV INFECT DIS, V11, P369
  • [2] Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
    Arikan, S
    Lozano-Chiu, M
    Paetznick, V
    Nangia, S
    Rex, JH
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) : 3946 - 3951
  • [3] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
    Boutati, EI
    Anaissie, EJ
    [J]. BLOOD, 1997, 90 (03) : 999 - 1008
  • [4] Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp.
    Bouza, E
    Muñoz, P
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 : 76 - 85
  • [5] BUTKA BJ, 1984, AM REV RESPIR DIS, V130, P1180
  • [6] Practice guidelines for the management of patients with blastomycosis
    Chapman, SW
    Bradsher, RW
    Campbell, GD
    Pappas, PG
    Kauffman, CA
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) : 679 - 683
  • [7] Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
    Diekema, DJ
    Messer, SA
    Hollis, RJ
    Jones, RN
    Pfaller, MA
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) : 3623 - 3626
  • [8] Practice guidelines for the treatment of coccidioidomycosis
    Galgiani, JN
    Ampel, NM
    Catanzaro, A
    Johnson, RH
    Stevens, DA
    Williams, PL
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) : 658 - 661
  • [9] FAILURE OF KETOCONAZOLE IN AN IMMUNOSUPPRESSED PATIENT WITH PULMONARY BLASTOMYCOSIS
    GREENE, NB
    BAUGHMAN, RP
    KIM, CK
    ROSELLE, GA
    [J]. CHEST, 1985, 88 (04) : 640 - 641
  • [10] Uncommon opportunistic fungi: new nosocomial threats
    Groll, AH
    Walsh, TJ
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 : 8 - 24